Objective To detect IgG antibody against Candida enolase in the sera of patients with autoimmune diseases. Methods Using purified recombinant Candida enolase as the coating antigen, an ELISA was established for enolase IgG antibody detection and the reactive conditions were optimized. The enolase IgG antibody in the sera from patients with autoimmune diseases and healthy controls were detected by ELISA. The specificity of the positive sera was confirmed by Western blotting. Results The study collected 70 serum samples from the patients with autoimmune diseases and 44 from the healthy individuals. ELISA showed anti-Candida enolase IgG antibody in 19 cases of the autoimmune disease group and and 3 cases of the healthy control group, the positive rates of which were 27.14% (19/70) and 6.82% (3/44), respectively. In the autoimmune disease group, the positive rate of anti-Candida enolase IgG antibody in the systemic lupus erythematosus patients was 45.8% (11/24), significant higher than that in the rheumatoid arthritis patients (11.8%, 2/17). Western blotting validated the specificity of the positive sera. Conclusion The positive rate of anti-Candida enolase IgG antibody in patients with autoimmune disease is high, which would be an interference factor in the application of IgG antibody detection for the diagnosis of invasive candidiasis.
Download full-text PDF |
Source |
---|
Immune deficits after CD19 chimeric antigen receptor (CAR) T-cell therapy can be long-lasting, predisposing patients to infections and non-relapse mortality. In B-cell non-Hodgkin lymphoma (B-NHL), the prognostic impact of immune reconstitution (IR) remains ill-defined, and detailed cross-product comparisons have not been performed to date. In this retrospective observational study, we longitudinally characterized lymphocyte subsets and immunoglobulin levels in 105 B-NHL patients to assess patterns of immune recovery arising after CD19 CAR-T.
View Article and Find Full Text PDFJ Clin Pathol
January 2025
Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, School of Medicine, University of Leeds, Leeds, LS9 7TF, UK.
Aims: Establishment of a protocol for routine single-molecule localisation microscopy (SMLM) imaging on formalin fixed paraffin embedded (FFPE) tissue using medical renal disease including minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS).
Methods: Protocol for normal and diseased renal FFPE tissue was developed to investigate the clinical diagnostic potential of SMLM. Antibody concentrations were determined for confocal microscopy and transferred to SMLM.
Lancet Microbe
January 2025
Jenner Institute, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Background: R21 is a novel malaria vaccine, composed of a fusion protein of the malaria circumsporozoite protein and hepatitis B surface antigen. Following favourable safety and immunogenicity in a phase 1 study, we aimed to assess the efficacy of R21 administered with Matrix-M (R21/MM) against clinical malaria in adults from the UK who were malaria naive in a controlled human malaria infection study.
Methods: In this open-label, partially blinded, phase 1-2A controlled human malaria infection study undertaken in Oxford, Southampton, and London, UK, we tested five novel vaccination regimens of R21/MM.
PLoS One
January 2025
Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada.
Primary and secondary antibody deficiencies (PAD and SAD) are amongst the most prevalent immunodeficiency syndromes, often necessitating long-term immune globulin replacement therapy (IRT). Both intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) have demonstrated efficacy in antibody deficiency. Comparative analyses of these two routes of administration are limited to nurse-administered IVIG and home therapy with self-administered SCIG.
View Article and Find Full Text PDFJ Appl Lab Med
January 2025
ARUP Laboratories, Salt Lake City, UT, United States.
Background: Detection of serum-specific immunoglobulin G (sIgG) to Aspergillus fumigatus traditionally relied on precipitin assays, which lack standardization and have poor analytical sensitivity. Automated quantitative immunoassays are now more widely used alternatives. A challenge, however, is determining reference interval (RI) cutoffs indicative of disease presence.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!